Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade in Metastatic Non-Clear Cell RCC
NCT00276614Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Apr 2006
- Primary completion
- Jul 2009
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in non-clear cell renal cell carcinoma (nccRCC), sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Objective Response Rate at 2 months. Started Apr 2006; status: completed.
02
Drugs
bortezomib
03
Conditions
non-clear cell renal cell carcinoma (nccRCC)
Beyond the preview
Go deeper on NCT00276614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00276614.